Linked Life Data

10885368

Source:http://linkedlifedata.com/resource/pubmed/id/10885368

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9220
pubmed:dateCreated
2000-7-20
pubmed:abstractText
An HIV-1 vaccine offers the best long-term hope to control the AIDS pandemic, especially in less-developed countries. To ensure its future availability we need to increase our research efforts today, including clinical trials. Although small-scale clinical trials of HIV-1 vaccines have been underway since 1987, the first phase III efficacy trials started only recently in the USA and Thailand. Initial results from these trials will be available within the next 2-3 years, and we must start planning now how vaccines should be used if found to be effective. In the meantime, the continuing promotion of the parallel development and assessment of other candidate vaccines is important. Financial mechanisms should also be developed as an incentive to industry and to ensure equitable distribution of future vaccines in less-developed countries. Moreover, a concerted effort is needed to ensure the development and future availability of appropriate vaccines for Africa.
pubmed:keyword
http://linkedlifedata.com/resource/pubmed/keyword/Acquired Immunodeficiency..., http://linkedlifedata.com/resource/pubmed/keyword/Africa, http://linkedlifedata.com/resource/pubmed/keyword/Clinical Research, http://linkedlifedata.com/resource/pubmed/keyword/Developing Countries, http://linkedlifedata.com/resource/pubmed/keyword/Diseases, http://linkedlifedata.com/resource/pubmed/keyword/Economic Factors, http://linkedlifedata.com/resource/pubmed/keyword/Hiv Infections--prevention and..., http://linkedlifedata.com/resource/pubmed/keyword/Progress Report, http://linkedlifedata.com/resource/pubmed/keyword/Research And Development, http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology, http://linkedlifedata.com/resource/pubmed/keyword/TECHNOLOGY, http://linkedlifedata.com/resource/pubmed/keyword/VACCINES, http://linkedlifedata.com/resource/pubmed/keyword/Viral Diseases
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0140-6736
pubmed:author
pubmed:issnType
Print
pubmed:day
10
pubmed:volume
355
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2061-6
pubmed:dateRevised
2007-11-15
pubmed:otherAbstract
PIP: An HIV-1 vaccine offers the best long-term hope to control the AIDS pandemic, especially in less-developed countries. To ensure its future availability, an increase in immediate research efforts, including clinical trials is necessary. Although small-scale clinical trials of HIV-1 vaccines have been underway since 1987, the phase 3 efficacy trials started only recently in the US and Thailand. Initial results of these trials will be available within the next 2-3 years, and researchers must start planning how the vaccines should be used if found effective. In the meantime, the continuing promotion of the parallel development and assessment of other candidate vaccines is important. Financial mechanisms should also be developed as an incentive to industry and to ensure equitable distribution of future vaccines in less-developed countries. Moreover, a concerted effort is needed to ensure the development and future availability of appropriate vaccines for Africa.
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?
pubmed:affiliation
WHO-UNAIDS HIV Vaccine Initiative, Health Technology and Pharmaceuticals, WHO, Geneva, Switzerland. esparzaj@unaids.org
pubmed:publicationType
Journal Article, Review